Guideline aims to recognize the risks, signs, and symptoms of acute HIV infection and to promote HIV testing in individuals presenting with flu-like symptoms or viral syndromes. It provides recommendations for diagnostic testing, treatment, and prevention services to improve patient health and reduc

0 views • 19 slides

This update highlights key points from the PMK No. 23/2022 on combating HIV, AIDS, and STIs. It covers terminologies, goals for eliminating HIV and AIDS by 2030, and strategies such as PrEP and PEP. The guidelines emphasize timely interventions like Post-Exposure Prophylaxis (PEP) and Pre-Exposure P

3 views • 38 slides

In sub-Saharan Africa, a study was conducted among Lake Victoria fishermen in Kenya to assess the effectiveness of a social network-based intervention in improving HIV testing and linkage outcomes. Results showed significantly higher rates of HIV self-testing and linkage to health facilities in the

0 views • 19 slides

Cardiovascular disease is a growing concern in individuals living with HIV, despite advancements in treatment. The REPRIEVE Trial sheds light on the importance of assessing cardiovascular risk and implementing primary prevention measures in this population. Dr. Grinspoon's financial disclosures and

0 views • 35 slides

HIV and AIDS are closely related, with HIV being the virus that leads to AIDS. HIV weakens the immune system by attacking specific white blood cells, while AIDS is the advanced stage of HIV infection. Prevention is crucial as AIDS is a deadly, incurable disease. The transmission of HIV primarily occ

4 views • 14 slides

The REPRIEVE trial focuses on developing a cardiovascular disease prevention strategy for individuals living with HIV. It addresses the increased risk of CVD in this population, even with good viral suppression. The study evaluates the use of pitavastatin, a statin with anti-inflammatory properties,

1 views • 33 slides

Explore how differentiated care is revolutionizing HIV service delivery by shifting the focus to client-centered approaches. Learn about the current challenges in facility-based care, the needs of people living with HIV, best practices from various countries, and innovative ways to provide different

0 views • 8 slides

HIV, a member of the lentivirus subfamily of retroviruses, causes Acquired Immunodeficiency Syndrome (AIDS). HIV-1 and HIV-2 have distinct characteristics, with HIV-1 being global and HIV-2 primarily in West Africa. The virus encodes reverse transcriptase and has an envelope containing glycoproteins

1 views • 31 slides

GLP-1 receptor agonists offer a promising therapeutic approach for weight management in individuals with HIV. Weight gain is a common issue, exacerbated by antiretroviral therapy, and can lead to metabolic risks. This presentation by Dr. Suman Srinivasa discusses the potential of GLP-1 receptor agon

2 views • 32 slides

Communicable Disease Harm Reduction Section collaborated with Simple HealthKit to offer free HIV, syphilis, gonorrhea, chlamydia, and trichomoniasis testing to Wisconsin residents over 18 from August 25, 2023, to October 20, 2023. The aim was to make HIV and STI testing more accessible to those with

0 views • 23 slides

Combination antiretroviral therapy (ART) is effective against HIV but can lead to drug resistance if not taken consistently. HIV mutates rapidly, increasing the risk of drug-resistant strains emerging. Learn about the causes, types of resistance, testing methods, and prevention strategies to combat

0 views • 23 slides

HIV Post-Exposure Prophylaxis (PEP) is a crucial emergency medical response for individuals exposed to HIV, aiming to prevent infection. It involves a regimen of medications, tests, and counseling services initiated within 72 hours of exposure. HIV transmission occurs through body fluids like blood,

3 views • 27 slides

Human Immunodeficiency Virus (HIV) is a retrovirus causing Acquired Immunodeficiency Syndrome (AIDS). HIV leads to immune system destruction, making individuals vulnerable to opportunistic infections and tumors. Common sexually transmitted diseases like syphilis, chlamydia, and gonorrhea are discuss

6 views • 15 slides

This content provides an overview of the relationship between TB and HIV, emphasizing the importance of testing HIV patients for latent TB infection and TB patients for HIV. It also outlines the guidelines for managing these co-infections, including diagnostic tests, treatment strategies, and patien

0 views • 17 slides

West Sussex's HIV testing plan for 2022-2025 focuses on reducing domestic transmissions by implementing targeted strategies in primary and secondary care settings. While overall prevalence is low, certain areas in West Sussex exhibit higher rates, necessitating tailored testing approaches. The plan

0 views • 6 slides

Exploring the various co-morbidities associated with HIV infection and factors contributing to their development. Discussions on disease clusters, impact of risk factors such as smoking and cardiovascular disease, and comorbidities in parents of PLWH compared to HIV-negative individuals. Insights in

0 views • 14 slides

PEPFAR is intensifying efforts on partner notification services for HIV prevention to address the global issue of undiagnosed HIV cases. The initiative aims to improve testing strategies, increase testing volumes, and enhance epidemic control. By reaching HIV testing targets and implementing efficie

0 views • 24 slides

Understanding the importance of early diagnosis in HIV-infected infants and children is crucial for timely intervention and improved health outcomes. This session covers testing algorithms, initiation of antiretroviral therapy, viral load monitoring, and legal issues related to HIV testing in childr

2 views • 31 slides

This study led by Dr. Geoffrey Chipungu, an HIV/AIDS Specialist at UNICEF ESARO, explores the rates, trends, and factors associated with HIV viral load suppression (VLS) in children. The research reveals sub-optimal VLS rates in children compared to adults, highlighting the need for improved policie

5 views • 12 slides

Update on advanced HIV disease in South Africa highlights progress in reducing AIDS-related deaths, prevalence rates, and advancements in coordinating and implementing policies and guidelines for HIV/AIDS response. The report covers statistics on HIV prevalence, ART facilities, mortality rates, and

0 views • 17 slides

HIV, Human Immunodeficiency Virus, attacks the immune system and can progress to AIDS if left untreated. Antiretroviral Therapy (ART) helps control HIV, allowing individuals to live healthy lives. The stages of HIV include Acute Infection, Chronic Infection, and the most severe stage, AIDS. Early de

0 views • 29 slides

This content provides detailed instructions for conducting HIV rapid tests using three different kits: Determine HIV-1/2 Rapid Test, Uni-Gold HIV-1/2 Rapid Test, and Bioline HIV-1/2 Rapid Test. The instructions include steps such as specimen collection, test device preparation, result interpretation

0 views • 5 slides

The study focuses on genotype-directed dosing of Efavirenz in children with HIV, aiming to optimize treatment options and dosages based on genetic factors. It explores the challenges in treating children with HIV, especially in resource-limited settings, and discusses the impact of genetic variation

0 views • 21 slides

August 18, 2020, marked the 30th anniversary of the Ryan White CARE Act, a landmark legislation that established the Ryan White HIV/AIDS Program providing care and treatment services to individuals with HIV in the U.S. The Act has been amended several times to extend and revise its purpose, no longe

0 views • 21 slides

Currently in the United States, a significant portion of individuals living with HIV are 50 years or older, facing the challenges of both aging and HIV. The Ryan White Planning Council Aged Needs Assessment 2019 aims to address the unique needs of individuals aged 50 and above living with HIV in New

0 views • 14 slides

This presentation by Tim Horn, MS, delves into the effects of drug pricing and generics on Ryan White HIV/AIDS Programs, focusing on cost containment, program income, challenges with antiretroviral drug pricing, and the role of generic drugs in mitigating costs. The discussion also covers the 340B D

0 views • 31 slides

Streamlined HIV care models aim to reduce the economic burden faced by HIV-infected adults by minimizing healthcare costs and improving access to care. The SEARCH trial in Kenya and Uganda implemented population-based testing and supported linkage to antiretroviral therapy (ART) regardless of CD4 co

2 views • 22 slides

This training session focuses on the relationship between undernutrition and HIV, discussing how HIV/AIDS affects nutrition among People Living with HIV (PLHIV). It covers the benefits of good nutrition for PLHIV and provides recommendations for Nutrition Assessment, Counselling, and Support (NACS)

1 views • 27 slides

Human Immunodeficiency Virus (HIV) is a lentivirus that infects CD4 T lymphocytes, leading to Acquired Immunodeficiency Syndrome (AIDS). Cutaneous manifestations of HIV/AIDS vary depending on the stage of infection and CD4 T cell counts. Early signs include exanthem, oral hairy leukoplakia, candidia

0 views • 17 slides

In response to the HIV/AIDS pandemic, this study focuses on the effectiveness of Pre-Exposure Prophylaxis (PrEP) in reducing HIV transmission among African American men who have sex with men in Orangeburg, SC. The research aims to investigate the impact of PrEP compared to condom use, and the necess

0 views • 6 slides

Maria, a pregnant woman in Malawi, faces the challenge of an unexpected pregnancy and a positive HIV diagnosis. The scenario explores her concerns, midwifery diagnosis, preparation for HIV testing, disclosure of results, and maintaining confidentiality in antenatal care. It also delves into factors

0 views • 10 slides

12.7 million people worldwide inject drugs, with 1.7 million of them living with HIV. The prevalence of HIV among people who inject drugs is 13.1%, highlighting the need for comprehensive service provision including testing, needle programs, opioid therapy, and antiretroviral treatment. The data als

0 views • 4 slides

This presentation highlights the significance of Regenerating Islet-Derived Protein-3 (REG3) and Intestinal Fatty Acid Binding Protein (I-FABP) in microbial translocation, inflammation, and reservoir size in individuals living with HIV. REG3 and I-FABP serve as markers of gut epithelial damage and p

0 views • 7 slides

This training module provides a comprehensive guide on conducting rapid HIV testing using the INSTI HIV rapid test. It covers organizing materials, performing blood collection, conducting the test, and interpreting results. The INSTI HIV rapid test is licensed in Canada and approved in Ontario for r

0 views • 12 slides

Explore the latest research presented by Gilead at CROI 2023 in Seattle, featuring abstracts on HIV treatment response predictors, long-acting Lenacapavir, F/TAF outcomes, HIV prevention, and exciting progress in HIV cure research. Don't miss the insightful findings and promising developments in the

0 views • 16 slides

This content provides information on HIV/AIDS prevention, including ways to get HIV, common body fluids transmitting HIV, ways to prevent HIV, and risk reduction strategies. It also includes steps for using a condom and guidelines for handling unsafe behaviors through the SWAT method. The curriculum

0 views • 19 slides

Explore the pivotal study on HIV criminalization in the EECA region, led by women living with HIV who delved deep into local legislation and documented cases. The research prioritized safety, confidentiality, and participant protection, unveiling the gendered impact of HIV criminalization. From gend

0 views • 5 slides

Global declines in HIV testing and reductions in new initiators, coupled with disruptions in HIV services due to COVID-19, pose challenges for future healthcare. Short-term disturbances could lead to increased HIV-related mortality, emphasizing the need for program responses to mitigate adverse effe

0 views • 10 slides

HIV/AIDS presents complex medical and psychiatric challenges, including HIV-Associated Neurocognitive Disorders (HANDs), which impact patients, families, and caregivers. This presentation by Dr. Mary Ann Adler Cohen provides insights into the prevalence, impact, diagnosis, and treatment of HANDs, em

0 views • 56 slides

Study on long-acting lenacapavir in heavily treatment-experienced HIV individuals after 104 weeks revealed emergence of lenacapavir resistance-associated mutations. Lenacapavir, a potent HIV-1 capsid inhibitor, has shown activity against ARV-resistant strains. The CAPELLA study analyzed lenacapavir

0 views • 11 slides